Summary
- Novo Nordisk’s Ozempic may decrease the risk of opioid overdoses in patients with Type 2 diabetes and opioid use disorder
- GLP-1 drugs, including semaglutide, show potential benefits beyond regulating blood sugar
- Study suggests a 58% lower risk of opioid overdose in patients who took semaglutide compared to other diabetes medications
- More research is needed to confirm the effectiveness of GLP-1 drugs in treating opioid use disorder